Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Graft vs Host Disease | 226 | 2024 | 2951 | 16.830 |
Why?
|
Hematopoietic Stem Cell Transplantation | 223 | 2024 | 5425 | 11.220 |
Why?
|
Transplantation Conditioning | 97 | 2024 | 1597 | 6.670 |
Why?
|
Cord Blood Stem Cell Transplantation | 33 | 2021 | 314 | 5.590 |
Why?
|
Myelodysplastic Syndromes | 49 | 2023 | 1351 | 5.370 |
Why?
|
Hematologic Neoplasms | 59 | 2023 | 1820 | 3.830 |
Why?
|
Transplantation, Homologous | 118 | 2024 | 4771 | 3.270 |
Why?
|
Sirolimus | 25 | 2020 | 1562 | 3.140 |
Why?
|
Tacrolimus | 23 | 2023 | 741 | 2.260 |
Why?
|
Leukemia, Myeloid, Acute | 33 | 2024 | 3497 | 2.050 |
Why?
|
Immunosuppressive Agents | 36 | 2022 | 4147 | 1.990 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 15 | 2016 | 272 | 1.770 |
Why?
|
Leukemia | 17 | 2021 | 1507 | 1.640 |
Why?
|
Fetal Blood | 17 | 2022 | 1317 | 1.630 |
Why?
|
Chronic Disease | 96 | 2024 | 9144 | 1.460 |
Why?
|
Hepatic Veno-Occlusive Disease | 9 | 2022 | 220 | 1.250 |
Why?
|
Interleukin-2 | 14 | 2022 | 1887 | 1.210 |
Why?
|
Bone Marrow Transplantation | 16 | 2023 | 2763 | 1.190 |
Why?
|
Mouth Diseases | 7 | 2019 | 239 | 1.110 |
Why?
|
Methotrexate | 18 | 2022 | 1720 | 1.110 |
Why?
|
Histocompatibility Testing | 20 | 2021 | 742 | 1.040 |
Why?
|
Acetamides | 3 | 2023 | 249 | 0.960 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 8 | 2014 | 694 | 0.950 |
Why?
|
Stem Cell Transplantation | 14 | 2020 | 1618 | 0.950 |
Why?
|
Disease-Free Survival | 53 | 2023 | 6891 | 0.920 |
Why?
|
National Institutes of Health (U.S.) | 14 | 2022 | 780 | 0.920 |
Why?
|
Middle Aged | 219 | 2023 | 213127 | 0.870 |
Why?
|
Humans | 366 | 2024 | 742088 | 0.860 |
Why?
|
Myeloablative Agonists | 14 | 2018 | 218 | 0.840 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2023 | 1377 | 0.840 |
Why?
|
Adult | 220 | 2023 | 213712 | 0.830 |
Why?
|
HLA Antigens | 10 | 2019 | 1382 | 0.830 |
Why?
|
T-Lymphocytes, Regulatory | 20 | 2022 | 2986 | 0.760 |
Why?
|
Aged | 164 | 2023 | 162944 | 0.750 |
Why?
|
Vidarabine | 12 | 2021 | 345 | 0.720 |
Why?
|
Survival Analysis | 51 | 2019 | 10248 | 0.720 |
Why?
|
Recurrence | 45 | 2023 | 8333 | 0.720 |
Why?
|
Histocompatibility | 6 | 2016 | 330 | 0.710 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2014 | 640 | 0.690 |
Why?
|
Male | 218 | 2023 | 349538 | 0.690 |
Why?
|
Bronchiolitis Obliterans | 7 | 2022 | 193 | 0.680 |
Why?
|
Adrenal Cortex Hormones | 7 | 2020 | 1847 | 0.670 |
Why?
|
Busulfan | 11 | 2021 | 262 | 0.650 |
Why?
|
Acute Disease | 32 | 2020 | 7141 | 0.650 |
Why?
|
Intention to Treat Analysis | 3 | 2021 | 425 | 0.650 |
Why?
|
B-Lymphocytes | 14 | 2022 | 4664 | 0.640 |
Why?
|
Female | 219 | 2023 | 379592 | 0.640 |
Why?
|
Survival Rate | 43 | 2021 | 12773 | 0.630 |
Why?
|
Consensus | 10 | 2022 | 2935 | 0.610 |
Why?
|
Hematology | 1 | 2020 | 219 | 0.610 |
Why?
|
B-Cell Activating Factor | 8 | 2018 | 119 | 0.590 |
Why?
|
Steroids | 9 | 2023 | 931 | 0.580 |
Why?
|
Transplantation, Autologous | 12 | 2023 | 2123 | 0.560 |
Why?
|
Graft vs Leukemia Effect | 6 | 2020 | 109 | 0.550 |
Why?
|
Mouth Mucosa | 4 | 2018 | 434 | 0.550 |
Why?
|
Anemia, Aplastic | 2 | 2015 | 226 | 0.540 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2018 | 1515 | 0.540 |
Why?
|
Blood Donors | 5 | 2019 | 355 | 0.530 |
Why?
|
Young Adult | 86 | 2022 | 56350 | 0.530 |
Why?
|
Radiopharmaceuticals | 4 | 2020 | 2658 | 0.520 |
Why?
|
Consumer Health Information | 1 | 2017 | 210 | 0.510 |
Why?
|
Graft Survival | 16 | 2021 | 3733 | 0.510 |
Why?
|
Piperidines | 4 | 2021 | 1602 | 0.510 |
Why?
|
Lymphoma | 7 | 2016 | 1873 | 0.500 |
Why?
|
Access to Information | 1 | 2017 | 320 | 0.490 |
Why?
|
Prognosis | 41 | 2023 | 29010 | 0.490 |
Why?
|
Whole-Body Irradiation | 5 | 2019 | 449 | 0.490 |
Why?
|
Oral Medicine | 2 | 2016 | 31 | 0.490 |
Why?
|
Treatment Outcome | 64 | 2021 | 62966 | 0.480 |
Why?
|
Protein Kinase Inhibitors | 5 | 2021 | 5522 | 0.480 |
Why?
|
Patient Selection | 2 | 2020 | 4214 | 0.470 |
Why?
|
Azacitidine | 3 | 2024 | 347 | 0.470 |
Why?
|
16,16-Dimethylprostaglandin E2 | 1 | 2013 | 22 | 0.470 |
Why?
|
BK Virus | 3 | 2020 | 129 | 0.450 |
Why?
|
Stomatitis | 4 | 2016 | 269 | 0.450 |
Why?
|
Clinical Trials as Topic | 14 | 2022 | 7901 | 0.440 |
Why?
|
Peer Review, Research | 1 | 2016 | 329 | 0.440 |
Why?
|
Receptors, KIR | 1 | 2013 | 113 | 0.430 |
Why?
|
Elafin | 1 | 2012 | 33 | 0.430 |
Why?
|
Adolescent | 82 | 2022 | 85649 | 0.430 |
Why?
|
Nuclear Medicine | 1 | 2015 | 233 | 0.420 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2018 | 689 | 0.420 |
Why?
|
Melphalan | 6 | 2020 | 431 | 0.420 |
Why?
|
Comprehension | 1 | 2017 | 608 | 0.420 |
Why?
|
Antibodies, Monoclonal | 12 | 2022 | 9274 | 0.410 |
Why?
|
Germinal Center | 3 | 2022 | 377 | 0.400 |
Why?
|
Tissue Donors | 19 | 2023 | 2205 | 0.400 |
Why?
|
Skin Diseases | 7 | 2020 | 1065 | 0.400 |
Why?
|
Retrospective Studies | 73 | 2023 | 77098 | 0.400 |
Why?
|
CD8-Positive T-Lymphocytes | 13 | 2022 | 4438 | 0.400 |
Why?
|
Recovery of Function | 2 | 2019 | 2924 | 0.390 |
Why?
|
Lymphoma, B-Cell | 3 | 2017 | 930 | 0.390 |
Why?
|
Antibodies | 4 | 2017 | 2459 | 0.390 |
Why?
|
Prospective Studies | 45 | 2023 | 53187 | 0.390 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 6 | 2021 | 1596 | 0.380 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2023 | 4029 | 0.380 |
Why?
|
Severity of Illness Index | 20 | 2020 | 15530 | 0.370 |
Why?
|
Photopheresis | 3 | 2019 | 24 | 0.370 |
Why?
|
Siblings | 9 | 2019 | 854 | 0.370 |
Why?
|
Cyclophosphamide | 7 | 2023 | 2236 | 0.370 |
Why?
|
Quality of Life | 22 | 2024 | 12730 | 0.360 |
Why?
|
Angiogenesis Inducing Agents | 3 | 2016 | 282 | 0.360 |
Why?
|
Immunoconjugates | 1 | 2017 | 897 | 0.350 |
Why?
|
Primary Myelofibrosis | 2 | 2023 | 214 | 0.350 |
Why?
|
Cytomegalovirus Infections | 4 | 2023 | 817 | 0.350 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 2 | 2023 | 97 | 0.340 |
Why?
|
Lectins, C-Type | 1 | 2012 | 588 | 0.340 |
Why?
|
Killer Cells, Natural | 8 | 2022 | 2133 | 0.330 |
Why?
|
Leukemia, Myeloid | 6 | 2021 | 705 | 0.330 |
Why?
|
Language | 1 | 2017 | 1458 | 0.320 |
Why?
|
Drug Resistance | 4 | 2019 | 1608 | 0.320 |
Why?
|
Transplantation Chimera | 6 | 2015 | 612 | 0.310 |
Why?
|
fms-Like Tyrosine Kinase 3 | 3 | 2016 | 491 | 0.310 |
Why?
|
Telomerase | 3 | 2021 | 729 | 0.310 |
Why?
|
rho-Associated Kinases | 2 | 2021 | 279 | 0.300 |
Why?
|
Remission Induction | 10 | 2021 | 2384 | 0.290 |
Why?
|
Virus Activation | 3 | 2019 | 319 | 0.280 |
Why?
|
Skin Neoplasms | 3 | 2023 | 5662 | 0.280 |
Why?
|
Iron Overload | 4 | 2012 | 243 | 0.280 |
Why?
|
Survivors | 8 | 2023 | 2286 | 0.280 |
Why?
|
Antineoplastic Agents | 11 | 2016 | 13655 | 0.270 |
Why?
|
Drugs, Generic | 1 | 2010 | 422 | 0.270 |
Why?
|
Pyrimidines | 6 | 2019 | 2933 | 0.270 |
Why?
|
Lymphoma, T-Cell, Peripheral | 2 | 2022 | 134 | 0.270 |
Why?
|
Combined Modality Therapy | 11 | 2019 | 8621 | 0.270 |
Why?
|
Premedication | 2 | 2008 | 257 | 0.260 |
Why?
|
United States | 29 | 2023 | 69693 | 0.260 |
Why?
|
Internet | 1 | 2017 | 3062 | 0.260 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2017 | 2099 | 0.260 |
Why?
|
Diagnostic Imaging | 2 | 2020 | 3507 | 0.260 |
Why?
|
Antigens, Neoplasm | 2 | 2012 | 1983 | 0.260 |
Why?
|
Polyomavirus Infections | 2 | 2019 | 196 | 0.260 |
Why?
|
Copper Radioisotopes | 3 | 2000 | 86 | 0.250 |
Why?
|
T-Lymphocytes, Helper-Inducer | 5 | 2019 | 986 | 0.250 |
Why?
|
Follow-Up Studies | 29 | 2023 | 39004 | 0.250 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2005 | 110 | 0.250 |
Why?
|
Mouth Neoplasms | 2 | 2022 | 601 | 0.250 |
Why?
|
Antilymphocyte Serum | 4 | 2016 | 491 | 0.250 |
Why?
|
Lymphocyte Transfusion | 2 | 2016 | 235 | 0.240 |
Why?
|
Hematopoietic Stem Cells | 5 | 2020 | 3381 | 0.240 |
Why?
|
Tumor Virus Infections | 2 | 2019 | 451 | 0.240 |
Why?
|
Cohort Studies | 29 | 2022 | 40450 | 0.240 |
Why?
|
HLA-C Antigens | 3 | 2016 | 147 | 0.240 |
Why?
|
Incidence | 24 | 2023 | 20928 | 0.230 |
Why?
|
T-Lymphocyte Subsets | 5 | 2019 | 1837 | 0.230 |
Why?
|
Antigens, Surface | 3 | 2017 | 1663 | 0.230 |
Why?
|
Niacinamide | 2 | 2016 | 416 | 0.230 |
Why?
|
Blood Platelets | 2 | 2013 | 2506 | 0.230 |
Why?
|
Graft Rejection | 5 | 2014 | 4393 | 0.220 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2016 | 227 | 0.220 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 22 | 0.220 |
Why?
|
DNA Methylation | 2 | 2014 | 4282 | 0.220 |
Why?
|
Gastrointestinal Agents | 2 | 2019 | 494 | 0.220 |
Why?
|
T-Lymphocytes | 7 | 2020 | 10163 | 0.220 |
Why?
|
Living Donors | 5 | 2015 | 618 | 0.220 |
Why?
|
Mycosis Fungoides | 3 | 2014 | 163 | 0.220 |
Why?
|
Prednisone | 5 | 2021 | 1567 | 0.220 |
Why?
|
Genome, Mitochondrial | 1 | 2023 | 71 | 0.220 |
Why?
|
Pyrazoles | 3 | 2019 | 1970 | 0.220 |
Why?
|
Telomere | 2 | 2020 | 909 | 0.220 |
Why?
|
Decision Support Techniques | 3 | 2013 | 1952 | 0.210 |
Why?
|
Adenine | 4 | 2021 | 936 | 0.210 |
Why?
|
Phenylurea Compounds | 2 | 2016 | 526 | 0.210 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2022 | 35 | 0.210 |
Why?
|
Gastrointestinal Tract | 3 | 2020 | 814 | 0.210 |
Why?
|
Sezary Syndrome | 2 | 2014 | 76 | 0.210 |
Why?
|
Mutation | 11 | 2023 | 29717 | 0.210 |
Why?
|
Immunologic Memory | 5 | 2017 | 1348 | 0.200 |
Why?
|
Gallium Radioisotopes | 2 | 2020 | 178 | 0.200 |
Why?
|
Markov Chains | 3 | 2013 | 969 | 0.200 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2014 | 4414 | 0.200 |
Why?
|
Enzyme Inhibitors | 3 | 2022 | 3800 | 0.200 |
Why?
|
Isoantibodies | 3 | 2019 | 680 | 0.200 |
Why?
|
Lymphocyte Activation | 11 | 2022 | 5519 | 0.200 |
Why?
|
Administration, Topical | 2 | 2020 | 688 | 0.200 |
Why?
|
Time Factors | 21 | 2019 | 40054 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 2 | 2018 | 193 | 0.190 |
Why?
|
Age Factors | 13 | 2020 | 18355 | 0.190 |
Why?
|
Xerostomia | 1 | 2021 | 95 | 0.190 |
Why?
|
Opportunistic Infections | 1 | 2023 | 389 | 0.190 |
Why?
|
CD4-Positive T-Lymphocytes | 9 | 2020 | 4379 | 0.190 |
Why?
|
Follistatin | 2 | 2019 | 141 | 0.190 |
Why?
|
Child | 31 | 2023 | 77478 | 0.180 |
Why?
|
Boronic Acids | 3 | 2014 | 965 | 0.180 |
Why?
|
Protein Kinases | 2 | 2022 | 1638 | 0.180 |
Why?
|
Hematologic Diseases | 4 | 2018 | 498 | 0.180 |
Why?
|
Child, Preschool | 23 | 2019 | 40955 | 0.180 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 169 | 0.180 |
Why?
|
Dental Caries | 2 | 2022 | 415 | 0.180 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 256 | 0.180 |
Why?
|
Leukemia, Experimental | 1 | 2020 | 246 | 0.170 |
Why?
|
Receptors, CXCR5 | 2 | 2016 | 92 | 0.170 |
Why?
|
Social Class | 2 | 2018 | 1995 | 0.170 |
Why?
|
Societies | 1 | 1999 | 104 | 0.160 |
Why?
|
Pyrazines | 3 | 2014 | 1231 | 0.160 |
Why?
|
Maximum Tolerated Dose | 2 | 2019 | 891 | 0.160 |
Why?
|
Isotope Labeling | 1 | 2000 | 414 | 0.160 |
Why?
|
Choroid Neoplasms | 1 | 1999 | 175 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 9 | 2021 | 6534 | 0.160 |
Why?
|
Pulmonary Blastoma | 1 | 1998 | 33 | 0.160 |
Why?
|
Cytokines | 5 | 2019 | 7317 | 0.160 |
Why?
|
Patient Education as Topic | 3 | 2017 | 2275 | 0.150 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2022 | 902 | 0.150 |
Why?
|
Receptors, Antigen, T-Cell | 5 | 2019 | 2524 | 0.150 |
Why?
|
Immunotherapy, Adoptive | 3 | 2021 | 1255 | 0.150 |
Why?
|
North America | 2 | 2018 | 1249 | 0.150 |
Why?
|
Skin | 4 | 2020 | 4353 | 0.150 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2023 | 569 | 0.150 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2021 | 651 | 0.150 |
Why?
|
Medicaid | 1 | 2011 | 2716 | 0.150 |
Why?
|
Endothelium, Vascular | 1 | 2010 | 4455 | 0.150 |
Why?
|
Immunologic Factors | 3 | 2014 | 1575 | 0.150 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 437 | 0.150 |
Why?
|
Salvage Therapy | 3 | 2018 | 1269 | 0.150 |
Why?
|
Prednisolone | 1 | 2018 | 333 | 0.150 |
Why?
|
alpha 1-Antitrypsin | 1 | 2018 | 164 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9185 | 0.150 |
Why?
|
Sulfonamides | 2 | 2024 | 1932 | 0.150 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2016 | 310 | 0.150 |
Why?
|
Myeloproliferative Disorders | 3 | 2016 | 603 | 0.150 |
Why?
|
Cryopreservation | 3 | 2021 | 664 | 0.140 |
Why?
|
Thrombotic Microangiopathies | 1 | 2018 | 132 | 0.140 |
Why?
|
Search Engine | 1 | 2017 | 144 | 0.140 |
Why?
|
Donor Selection | 1 | 2018 | 201 | 0.140 |
Why?
|
Graft vs Tumor Effect | 1 | 2016 | 72 | 0.140 |
Why?
|
Neoplasms, Second Primary | 2 | 2017 | 1052 | 0.140 |
Why?
|
Animals | 27 | 2022 | 168561 | 0.140 |
Why?
|
Cancer Vaccines | 3 | 2014 | 1021 | 0.140 |
Why?
|
Risk Factors | 24 | 2018 | 72145 | 0.140 |
Why?
|
Neoplasm, Residual | 2 | 2021 | 974 | 0.140 |
Why?
|
Early Diagnosis | 1 | 2021 | 1184 | 0.140 |
Why?
|
Arabinonucleosides | 1 | 2015 | 35 | 0.130 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1402 | 0.130 |
Why?
|
Adenine Nucleotides | 1 | 2015 | 121 | 0.130 |
Why?
|
Tandem Repeat Sequences | 1 | 2016 | 185 | 0.130 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2015 | 77 | 0.130 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 246 | 0.130 |
Why?
|
Organometallic Compounds | 1 | 1999 | 665 | 0.130 |
Why?
|
Registries | 5 | 2018 | 8077 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2018 | 11472 | 0.130 |
Why?
|
Receptors, CXCR3 | 1 | 2016 | 237 | 0.130 |
Why?
|
Chemokine CXCL10 | 1 | 2016 | 304 | 0.130 |
Why?
|
Drug Hypersensitivity | 1 | 2023 | 883 | 0.130 |
Why?
|
Antigens, CD19 | 1 | 2017 | 379 | 0.130 |
Why?
|
Stem Cell Factor | 1 | 2015 | 219 | 0.130 |
Why?
|
Interleukin-7 | 1 | 2015 | 142 | 0.130 |
Why?
|
Antifungal Agents | 2 | 2012 | 729 | 0.130 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 890 | 0.120 |
Why?
|
Oral Health | 1 | 2020 | 472 | 0.120 |
Why?
|
Hypersensitivity | 1 | 2023 | 1093 | 0.120 |
Why?
|
Monte Carlo Method | 1 | 2020 | 1254 | 0.120 |
Why?
|
Flow Cytometry | 6 | 2018 | 5975 | 0.120 |
Why?
|
Research Support as Topic | 1 | 1999 | 704 | 0.120 |
Why?
|
Mediastinal Neoplasms | 1 | 2017 | 421 | 0.120 |
Why?
|
Medicare | 2 | 2020 | 6532 | 0.120 |
Why?
|
Holmium | 1 | 2013 | 30 | 0.120 |
Why?
|
Thrombomodulin | 2 | 2016 | 102 | 0.120 |
Why?
|
Epidermal Growth Factor | 1 | 2017 | 709 | 0.120 |
Why?
|
Lymphocyte Depletion | 4 | 2016 | 608 | 0.120 |
Why?
|
Endpoint Determination | 1 | 2017 | 600 | 0.120 |
Why?
|
Fibrosis | 1 | 2021 | 2026 | 0.120 |
Why?
|
Bone Marrow | 5 | 2023 | 2941 | 0.120 |
Why?
|
Thermodynamics | 1 | 2015 | 594 | 0.120 |
Why?
|
Radioimmunotherapy | 1 | 2013 | 79 | 0.120 |
Why?
|
Lymphocyte Count | 4 | 2019 | 792 | 0.120 |
Why?
|
Adoptive Transfer | 1 | 2016 | 844 | 0.120 |
Why?
|
Ferritins | 4 | 2012 | 590 | 0.120 |
Why?
|
Varicose Veins | 1 | 1995 | 154 | 0.120 |
Why?
|
Drug Therapy, Combination | 6 | 2016 | 6483 | 0.110 |
Why?
|
Antigen-Presenting Cells | 2 | 2020 | 969 | 0.110 |
Why?
|
Fascia | 1 | 2014 | 135 | 0.110 |
Why?
|
Managed Care Programs | 1 | 1999 | 949 | 0.110 |
Why?
|
Glucagon | 1 | 1995 | 533 | 0.110 |
Why?
|
B-Lymphocyte Subsets | 2 | 2018 | 246 | 0.110 |
Why?
|
Consensus Development Conferences, NIH as Topic | 4 | 2014 | 28 | 0.110 |
Why?
|
Neoplasms | 5 | 2023 | 21596 | 0.110 |
Why?
|
Data Collection | 4 | 2018 | 3339 | 0.110 |
Why?
|
Small Molecule Libraries | 1 | 2018 | 721 | 0.110 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11039 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1071 | 0.110 |
Why?
|
Disease Management | 2 | 2020 | 2450 | 0.110 |
Why?
|
Cyclosporine | 1 | 2015 | 784 | 0.110 |
Why?
|
Joints | 1 | 2014 | 326 | 0.110 |
Why?
|
Chelation Therapy | 1 | 2012 | 67 | 0.110 |
Why?
|
Limbic Encephalitis | 1 | 2012 | 34 | 0.110 |
Why?
|
Viremia | 2 | 2019 | 735 | 0.100 |
Why?
|
Pyridones | 1 | 2017 | 712 | 0.100 |
Why?
|
Leukocytes, Mononuclear | 2 | 2016 | 1835 | 0.100 |
Why?
|
Roseolovirus Infections | 1 | 2012 | 45 | 0.100 |
Why?
|
Employment | 1 | 2018 | 1124 | 0.100 |
Why?
|
Topography, Medical | 1 | 2011 | 37 | 0.100 |
Why?
|
Mutagenesis, Insertional | 1 | 2014 | 655 | 0.100 |
Why?
|
STAT3 Transcription Factor | 1 | 2016 | 874 | 0.100 |
Why?
|
Phantoms, Imaging | 1 | 2020 | 2466 | 0.100 |
Why?
|
Herpesvirus 6, Human | 1 | 2012 | 95 | 0.100 |
Why?
|
Homeostasis | 3 | 2013 | 3335 | 0.100 |
Why?
|
Procarbazine | 1 | 2011 | 181 | 0.100 |
Why?
|
Gene Deletion | 1 | 2019 | 2751 | 0.100 |
Why?
|
Delirium | 1 | 2023 | 1608 | 0.100 |
Why?
|
Mycophenolic Acid | 2 | 2010 | 343 | 0.100 |
Why?
|
Iron Chelating Agents | 1 | 2012 | 139 | 0.100 |
Why?
|
Radionuclide Imaging | 1 | 2015 | 2027 | 0.100 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2016 | 647 | 0.100 |
Why?
|
Drug Administration Routes | 1 | 2011 | 153 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2014 | 2107 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 1758 | 0.100 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2749 | 0.100 |
Why?
|
Aftercare | 1 | 2017 | 860 | 0.100 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2009 | 1379 | 0.100 |
Why?
|
STAT5 Transcription Factor | 3 | 2017 | 259 | 0.100 |
Why?
|
Age of Onset | 1 | 2017 | 3266 | 0.100 |
Why?
|
Kinetics | 2 | 2015 | 6474 | 0.090 |
Why?
|
Cytomegalovirus | 2 | 2018 | 730 | 0.090 |
Why?
|
Therapeutic Equivalency | 1 | 2010 | 145 | 0.090 |
Why?
|
Bone Marrow Diseases | 1 | 2012 | 230 | 0.090 |
Why?
|
Practice Guidelines as Topic | 6 | 2018 | 7276 | 0.090 |
Why?
|
Clostridium Infections | 1 | 2017 | 548 | 0.090 |
Why?
|
Sickness Impact Profile | 1 | 2011 | 304 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2187 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 627 | 0.090 |
Why?
|
Melanoma, Experimental | 1 | 2013 | 559 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1967 | 0.090 |
Why?
|
International Cooperation | 2 | 2014 | 1421 | 0.090 |
Why?
|
Hand Strength | 1 | 2013 | 444 | 0.090 |
Why?
|
Immunophenotyping | 4 | 2018 | 1866 | 0.090 |
Why?
|
Gastrointestinal Diseases | 1 | 2018 | 1167 | 0.090 |
Why?
|
Vinblastine | 1 | 2011 | 490 | 0.090 |
Why?
|
Longitudinal Studies | 5 | 2018 | 13921 | 0.090 |
Why?
|
Mucocele | 1 | 2009 | 49 | 0.090 |
Why?
|
Tissue Distribution | 3 | 2013 | 2335 | 0.090 |
Why?
|
Haplotypes | 1 | 2016 | 2781 | 0.090 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2017 | 2455 | 0.090 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2011 | 246 | 0.090 |
Why?
|
Antibody Specificity | 1 | 2011 | 1094 | 0.090 |
Why?
|
Isoantigens | 1 | 2012 | 567 | 0.090 |
Why?
|
Mice, Inbred BALB C | 4 | 2020 | 6382 | 0.090 |
Why?
|
Proteins | 2 | 2022 | 6096 | 0.080 |
Why?
|
Erythema | 1 | 2010 | 254 | 0.080 |
Why?
|
Dexamethasone | 1 | 2016 | 1949 | 0.080 |
Why?
|
Transforming Growth Factor beta | 1 | 2017 | 2006 | 0.080 |
Why?
|
History, 21st Century | 1 | 2015 | 1533 | 0.080 |
Why?
|
Medical Oncology | 2 | 2023 | 2235 | 0.080 |
Why?
|
Diarrhea | 2 | 2017 | 1343 | 0.080 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 1995 | 859 | 0.080 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2009 | 187 | 0.080 |
Why?
|
Intestine, Small | 1 | 1995 | 1243 | 0.080 |
Why?
|
Oral Ulcer | 1 | 2009 | 96 | 0.080 |
Why?
|
Genetic Variation | 2 | 2021 | 6540 | 0.080 |
Why?
|
Mice, Inbred C57BL | 8 | 2020 | 21821 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3691 | 0.080 |
Why?
|
Proportional Hazards Models | 8 | 2017 | 12344 | 0.080 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11001 | 0.080 |
Why?
|
Thrombocytopenia | 1 | 2016 | 1171 | 0.080 |
Why?
|
Aminoglycosides | 2 | 2012 | 161 | 0.080 |
Why?
|
Hypertriglyceridemia | 1 | 2011 | 293 | 0.080 |
Why?
|
Cross Infection | 1 | 2017 | 1413 | 0.080 |
Why?
|
Myocardium | 2 | 2012 | 4775 | 0.080 |
Why?
|
Drug Monitoring | 2 | 2012 | 956 | 0.080 |
Why?
|
Spleen | 2 | 2016 | 2359 | 0.080 |
Why?
|
Lymphoproliferative Disorders | 1 | 2011 | 525 | 0.080 |
Why?
|
Antibodies, Viral | 3 | 2019 | 3164 | 0.080 |
Why?
|
E-Selectin | 1 | 2010 | 579 | 0.080 |
Why?
|
Mice | 13 | 2022 | 81045 | 0.080 |
Why?
|
Risk | 5 | 2011 | 9679 | 0.080 |
Why?
|
Pulmonary Edema | 1 | 2010 | 415 | 0.080 |
Why?
|
Range of Motion, Articular | 1 | 2014 | 1577 | 0.070 |
Why?
|
Drug Evaluation | 2 | 2006 | 637 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2948 | 0.070 |
Why?
|
Insurance Coverage | 1 | 2018 | 1895 | 0.070 |
Why?
|
Dry Eye Syndromes | 1 | 2011 | 382 | 0.070 |
Why?
|
Lymphoma, Follicular | 1 | 2011 | 435 | 0.070 |
Why?
|
Multivariate Analysis | 7 | 2017 | 12242 | 0.070 |
Why?
|
Hypolipidemic Agents | 1 | 2011 | 604 | 0.070 |
Why?
|
Cytogenetics | 1 | 2007 | 203 | 0.070 |
Why?
|
Ancillary Services, Hospital | 1 | 2006 | 23 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 457 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2012 | 4929 | 0.070 |
Why?
|
Drug Stability | 2 | 2013 | 290 | 0.070 |
Why?
|
RNA | 1 | 2016 | 2747 | 0.070 |
Why?
|
Immunity, Humoral | 1 | 2010 | 596 | 0.070 |
Why?
|
von Willebrand Factor | 1 | 2010 | 668 | 0.070 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2010 | 1155 | 0.070 |
Why?
|
Cells, Cultured | 4 | 2016 | 19223 | 0.070 |
Why?
|
Infant | 7 | 2017 | 35070 | 0.070 |
Why?
|
Treatment Failure | 3 | 2020 | 2615 | 0.070 |
Why?
|
Mice, Knockout | 5 | 2020 | 14554 | 0.070 |
Why?
|
Antigens, CD | 4 | 2022 | 4024 | 0.070 |
Why?
|
Transplantation Immunology | 3 | 2016 | 547 | 0.070 |
Why?
|
Leukocytes | 1 | 2014 | 2039 | 0.070 |
Why?
|
Walking | 1 | 2013 | 1177 | 0.070 |
Why?
|
Iron | 2 | 2012 | 1773 | 0.070 |
Why?
|
Heart | 1 | 1999 | 4462 | 0.070 |
Why?
|
Parathyroid Hormone | 1 | 2012 | 1801 | 0.070 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2007 | 206 | 0.070 |
Why?
|
Feasibility Studies | 3 | 2023 | 5062 | 0.070 |
Why?
|
H-Y Antigen | 1 | 2004 | 45 | 0.060 |
Why?
|
Medical Staff, Hospital | 1 | 2009 | 603 | 0.060 |
Why?
|
Phototherapy | 1 | 2008 | 377 | 0.060 |
Why?
|
Thymus Gland | 1 | 2010 | 1264 | 0.060 |
Why?
|
Length of Stay | 3 | 2008 | 6294 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2906 | 0.060 |
Why?
|
Mice, Mutant Strains | 2 | 2019 | 1866 | 0.060 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2012 | 1820 | 0.060 |
Why?
|
Peptides | 2 | 2015 | 4392 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 1668 | 0.060 |
Why?
|
Patients | 2 | 2023 | 892 | 0.060 |
Why?
|
Hypercholesterolemia | 1 | 2011 | 1149 | 0.060 |
Why?
|
Liver Diseases | 1 | 2013 | 1252 | 0.060 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2006 | 433 | 0.060 |
Why?
|
Lung Neoplasms | 2 | 1999 | 13019 | 0.060 |
Why?
|
Cardiology | 1 | 2015 | 1658 | 0.060 |
Why?
|
Syndrome | 3 | 2018 | 3248 | 0.060 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2005 | 131 | 0.060 |
Why?
|
Positron-Emission Tomography | 1 | 2020 | 6259 | 0.060 |
Why?
|
Organ Specificity | 3 | 2014 | 2003 | 0.060 |
Why?
|
Chemokines | 1 | 2008 | 954 | 0.060 |
Why?
|
Observer Variation | 1 | 2009 | 2593 | 0.060 |
Why?
|
Colitis | 1 | 2011 | 1149 | 0.060 |
Why?
|
Aged, 80 and over | 9 | 2021 | 57683 | 0.060 |
Why?
|
Diphtheria Toxin | 1 | 2004 | 255 | 0.060 |
Why?
|
Case-Control Studies | 6 | 2016 | 21719 | 0.060 |
Why?
|
Dendritic Cells | 1 | 2014 | 2723 | 0.060 |
Why?
|
Disease Progression | 6 | 2017 | 13256 | 0.060 |
Why?
|
Multicenter Studies as Topic | 2 | 2023 | 1661 | 0.060 |
Why?
|
Drug Combinations | 1 | 2008 | 1961 | 0.060 |
Why?
|
Influenza Vaccines | 1 | 2010 | 733 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 3915 | 0.060 |
Why?
|
Fever | 1 | 2010 | 1612 | 0.050 |
Why?
|
Mycoses | 1 | 2006 | 376 | 0.050 |
Why?
|
Statistics as Topic | 1 | 2009 | 2372 | 0.050 |
Why?
|
Drug Costs | 1 | 2010 | 1104 | 0.050 |
Why?
|
Amoxicillin | 1 | 2023 | 170 | 0.050 |
Why?
|
Disease Models, Animal | 6 | 2020 | 18006 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2020 | 8925 | 0.050 |
Why?
|
Interleukin-17 | 2 | 2020 | 900 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 94 | 0.050 |
Why?
|
Kidney | 1 | 2018 | 7167 | 0.050 |
Why?
|
Ambulatory Care | 3 | 2007 | 2706 | 0.050 |
Why?
|
Apoptosis | 3 | 2014 | 9715 | 0.050 |
Why?
|
Lung | 3 | 2016 | 9826 | 0.050 |
Why?
|
beta-Lactams | 1 | 2023 | 159 | 0.050 |
Why?
|
Macrophages | 1 | 2017 | 5655 | 0.050 |
Why?
|
Comorbidity | 3 | 2013 | 10372 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2017 | 10943 | 0.050 |
Why?
|
Genomics | 1 | 2018 | 5692 | 0.050 |
Why?
|
Translocation, Genetic | 1 | 2007 | 1417 | 0.050 |
Why?
|
Cell Proliferation | 4 | 2019 | 10472 | 0.050 |
Why?
|
Decision Making | 1 | 2016 | 3869 | 0.050 |
Why?
|
Succinimides | 1 | 2001 | 79 | 0.050 |
Why?
|
Skin Tests | 1 | 2023 | 612 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4553 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2014 | 5095 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2014 | 5385 | 0.050 |
Why?
|
Diterpenes | 1 | 2022 | 173 | 0.050 |
Why?
|
Tomography, Emission-Computed | 3 | 1999 | 1144 | 0.050 |
Why?
|
Oral Hygiene | 1 | 2022 | 125 | 0.050 |
Why?
|
Infant, Newborn | 3 | 2016 | 25575 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10578 | 0.050 |
Why?
|
Risk Assessment | 5 | 2018 | 23320 | 0.050 |
Why?
|
Self Report | 1 | 2012 | 3548 | 0.050 |
Why?
|
Penicillins | 1 | 2023 | 378 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 265 | 0.050 |
Why?
|
Mitochondria | 1 | 2014 | 3520 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 127 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 1999 | 5171 | 0.050 |
Why?
|
Stem Cells | 1 | 2014 | 3563 | 0.050 |
Why?
|
Forehead | 1 | 2021 | 69 | 0.050 |
Why?
|
Benzamides | 1 | 2006 | 1378 | 0.050 |
Why?
|
Histidine | 1 | 2001 | 313 | 0.050 |
Why?
|
DNA, Viral | 2 | 2019 | 2224 | 0.050 |
Why?
|
Triazoles | 1 | 2006 | 907 | 0.050 |
Why?
|
Ohio | 1 | 2021 | 337 | 0.050 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2022 | 906 | 0.050 |
Why?
|
DEAD-box RNA Helicases | 1 | 2023 | 375 | 0.050 |
Why?
|
Hodgkin Disease | 1 | 2008 | 1413 | 0.050 |
Why?
|
Musculoskeletal Diseases | 1 | 2006 | 581 | 0.040 |
Why?
|
Karyotyping | 2 | 2012 | 1243 | 0.040 |
Why?
|
ROC Curve | 2 | 2018 | 3528 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2016 | 1372 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2016 | 15244 | 0.040 |
Why?
|
Macaca nemestrina | 1 | 1999 | 23 | 0.040 |
Why?
|
Mouth | 2 | 2012 | 373 | 0.040 |
Why?
|
Karnofsky Performance Status | 1 | 2019 | 173 | 0.040 |
Why?
|
Thiosemicarbazones | 1 | 1999 | 15 | 0.040 |
Why?
|
Zirconium | 1 | 2020 | 100 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2011 | 2956 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2007 | 9941 | 0.040 |
Why?
|
Influenza, Human | 1 | 2010 | 1472 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 3862 | 0.040 |
Why?
|
Proteomics | 1 | 2012 | 3618 | 0.040 |
Why?
|
Mesocricetus | 1 | 1999 | 251 | 0.040 |
Why?
|
Immunoglobulin G | 3 | 2009 | 4554 | 0.040 |
Why?
|
Leukocyte Count | 2 | 2014 | 1583 | 0.040 |
Why?
|
Morbidity | 2 | 2016 | 1767 | 0.040 |
Why?
|
Cell Count | 2 | 2016 | 1831 | 0.040 |
Why?
|
Receptors, Complement 3d | 1 | 2018 | 118 | 0.040 |
Why?
|
Infection Control | 1 | 2006 | 962 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2017 | 1434 | 0.040 |
Why?
|
Crohn Disease | 1 | 2011 | 2301 | 0.040 |
Why?
|
Scleroderma, Localized | 1 | 2019 | 79 | 0.040 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2001 | 437 | 0.040 |
Why?
|
Radioisotopes | 1 | 2020 | 499 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 2023 | 1040 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 2 | 2000 | 8300 | 0.040 |
Why?
|
Health Status | 2 | 2011 | 4030 | 0.040 |
Why?
|
Prescriptions | 1 | 2021 | 387 | 0.040 |
Why?
|
Models, Biological | 1 | 2015 | 9581 | 0.040 |
Why?
|
Autoradiography | 1 | 1999 | 749 | 0.040 |
Why?
|
Pilot Projects | 3 | 2023 | 8297 | 0.040 |
Why?
|
Tumor Lysis Syndrome | 1 | 2018 | 42 | 0.040 |
Why?
|
Hematopoiesis | 2 | 2021 | 2066 | 0.040 |
Why?
|
Minnesota | 1 | 2018 | 343 | 0.040 |
Why?
|
Interinstitutional Relations | 1 | 1999 | 240 | 0.040 |
Why?
|
Sex Factors | 3 | 2019 | 10392 | 0.040 |
Why?
|
DNA, Mitochondrial | 1 | 2023 | 814 | 0.040 |
Why?
|
Carbon Radioisotopes | 1 | 1999 | 592 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 861 | 0.040 |
Why?
|
Interferon-gamma | 2 | 2020 | 3199 | 0.040 |
Why?
|
Models, Statistical | 1 | 2012 | 5100 | 0.040 |
Why?
|
Thrombopoietin | 1 | 2019 | 223 | 0.040 |
Why?
|
Gene Expression | 3 | 2016 | 7790 | 0.040 |
Why?
|
Cyclotrons | 1 | 1997 | 30 | 0.040 |
Why?
|
Dogs | 2 | 1999 | 3910 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9410 | 0.040 |
Why?
|
Endothelial Cells | 1 | 2010 | 3455 | 0.040 |
Why?
|
Manganese | 1 | 2020 | 408 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2019 | 3502 | 0.040 |
Why?
|
Costs and Cost Analysis | 4 | 2008 | 1679 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 2 | 2023 | 3014 | 0.040 |
Why?
|
Immune Tolerance | 2 | 2019 | 2257 | 0.040 |
Why?
|
Progesterone | 1 | 2021 | 773 | 0.040 |
Why?
|
Angiopoietin-1 | 1 | 2016 | 114 | 0.040 |
Why?
|
Lymphocyte Cooperation | 1 | 2016 | 112 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2014 | 8425 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3239 | 0.030 |
Why?
|
Chemokine CXCL9 | 1 | 2016 | 132 | 0.030 |
Why?
|
Neutrophils | 3 | 2016 | 3711 | 0.030 |
Why?
|
Vaccination | 2 | 2022 | 3256 | 0.030 |
Why?
|
Matrix Metalloproteinase 3 | 1 | 2016 | 134 | 0.030 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2016 | 226 | 0.030 |
Why?
|
Piperazines | 1 | 2006 | 2488 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1875 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2001 | 1181 | 0.030 |
Why?
|
Angiopoietin-2 | 1 | 2016 | 170 | 0.030 |
Why?
|
Melena | 1 | 1995 | 34 | 0.030 |
Why?
|
Health Maintenance Organizations | 2 | 1990 | 642 | 0.030 |
Why?
|
Brain | 2 | 1999 | 26343 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2021 | 870 | 0.030 |
Why?
|
Endoscopes, Gastrointestinal | 1 | 1995 | 60 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 3770 | 0.030 |
Why?
|
Lymphopoiesis | 1 | 2016 | 133 | 0.030 |
Why?
|
B-Cell Activation Factor Receptor | 1 | 2014 | 13 | 0.030 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2016 | 140 | 0.030 |
Why?
|
Cricetinae | 1 | 1999 | 2471 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2017 | 905 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2715 | 0.030 |
Why?
|
Head and Neck Neoplasms | 1 | 2009 | 2712 | 0.030 |
Why?
|
Rats | 3 | 2000 | 24265 | 0.030 |
Why?
|
Receptors, Interleukin-21 | 1 | 2014 | 33 | 0.030 |
Why?
|
Osteopontin | 1 | 2016 | 296 | 0.030 |
Why?
|
Genes, p53 | 1 | 2017 | 755 | 0.030 |
Why?
|
Transplants | 1 | 2016 | 208 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2017 | 617 | 0.030 |
Why?
|
Platelet Count | 1 | 2017 | 780 | 0.030 |
Why?
|
Lymphocytes | 2 | 2014 | 2614 | 0.030 |
Why?
|
Aging | 2 | 2010 | 8626 | 0.030 |
Why?
|
Phylogeny | 1 | 2001 | 2797 | 0.030 |
Why?
|
Antigens, CD34 | 1 | 2016 | 657 | 0.030 |
Why?
|
Pentetic Acid | 1 | 2013 | 213 | 0.030 |
Why?
|
Janus Kinase 2 | 1 | 2017 | 527 | 0.030 |
Why?
|
Forkhead Transcription Factors | 2 | 2011 | 1613 | 0.030 |
Why?
|
Oxazines | 1 | 2015 | 298 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 24913 | 0.030 |
Why?
|
Antigens, CD20 | 1 | 2014 | 198 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2009 | 6608 | 0.030 |
Why?
|
Yttrium Radioisotopes | 1 | 2013 | 93 | 0.030 |
Why?
|
Esophageal and Gastric Varices | 1 | 1995 | 207 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 1995 | 1420 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2016 | 880 | 0.030 |
Why?
|
Biopsy | 2 | 2017 | 6756 | 0.030 |
Why?
|
Algorithms | 4 | 2018 | 13853 | 0.030 |
Why?
|
HLA-A Antigens | 1 | 2013 | 228 | 0.030 |
Why?
|
Nucleic Acid Conformation | 1 | 2016 | 914 | 0.030 |
Why?
|
Antibody Formation | 1 | 2017 | 1402 | 0.030 |
Why?
|
Half-Life | 1 | 2013 | 658 | 0.030 |
Why?
|
Candidiasis, Oral | 1 | 2012 | 60 | 0.030 |
Why?
|
Pulmonary Fibrosis | 1 | 2017 | 526 | 0.030 |
Why?
|
Blood-Brain Barrier | 1 | 1999 | 1015 | 0.030 |
Why?
|
Infusions, Subcutaneous | 1 | 2012 | 42 | 0.030 |
Why?
|
Demography | 1 | 2017 | 1650 | 0.030 |
Why?
|
Signal Transduction | 2 | 2013 | 23387 | 0.030 |
Why?
|
Plasma Cells | 1 | 2016 | 592 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 1998 | 1769 | 0.030 |
Why?
|
Ethanol | 1 | 1999 | 1337 | 0.030 |
Why?
|
Glucocorticoids | 2 | 2012 | 2107 | 0.030 |
Why?
|
Area Under Curve | 1 | 2016 | 1653 | 0.030 |
Why?
|
CD40 Ligand | 1 | 2014 | 526 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2012 | 68 | 0.030 |
Why?
|
Vision Disorders | 1 | 1999 | 1057 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2016 | 1341 | 0.030 |
Why?
|
Morpholines | 1 | 2015 | 561 | 0.030 |
Why?
|
Gene Library | 1 | 2014 | 1076 | 0.030 |
Why?
|
HLA-B Antigens | 1 | 2013 | 353 | 0.030 |
Why?
|
Deferoxamine | 1 | 2012 | 151 | 0.030 |
Why?
|
Medication Adherence | 1 | 2023 | 2055 | 0.030 |
Why?
|
Death | 1 | 2016 | 675 | 0.030 |
Why?
|
Colonic Polyps | 1 | 1997 | 542 | 0.030 |
Why?
|
K562 Cells | 1 | 2013 | 632 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2940 | 0.020 |
Why?
|
ras Proteins | 1 | 2017 | 1060 | 0.020 |
Why?
|
Probability | 1 | 2017 | 2502 | 0.020 |
Why?
|
Aminopyridines | 1 | 2015 | 541 | 0.020 |
Why?
|
Salivary Glands | 1 | 2012 | 228 | 0.020 |
Why?
|
Cell Separation | 1 | 2016 | 1749 | 0.020 |
Why?
|
Interleukin-4 | 1 | 2014 | 1146 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2015 | 2505 | 0.020 |
Why?
|
Transplantation, Isogeneic | 1 | 2010 | 257 | 0.020 |
Why?
|
Methylprednisolone | 1 | 2012 | 388 | 0.020 |
Why?
|
Solubility | 1 | 2012 | 1083 | 0.020 |
Why?
|
International Agencies | 1 | 2011 | 240 | 0.020 |
Why?
|
Cell Size | 1 | 2012 | 643 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2203 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2557 | 0.020 |
Why?
|
Observation | 1 | 2011 | 312 | 0.020 |
Why?
|
Splenic Rupture | 1 | 2009 | 26 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 15056 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2005 | 4229 | 0.020 |
Why?
|
Sequence Analysis, DNA | 2 | 2016 | 4801 | 0.020 |
Why?
|
Interleukins | 1 | 2014 | 791 | 0.020 |
Why?
|
Filgrastim | 1 | 2009 | 132 | 0.020 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2009 | 91 | 0.020 |
Why?
|
Health Resources | 1 | 2016 | 911 | 0.020 |
Why?
|
Th17 Cells | 1 | 2016 | 765 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2007 | 12958 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2013 | 1613 | 0.020 |
Why?
|
Leukapheresis | 1 | 2009 | 131 | 0.020 |
Why?
|
Vascular Diseases | 1 | 2018 | 1155 | 0.020 |
Why?
|
Diagnostic Self Evaluation | 1 | 2011 | 230 | 0.020 |
Why?
|
Antibodies, Antinuclear | 1 | 2010 | 326 | 0.020 |
Why?
|
Dental Care for Chronically Ill | 1 | 2009 | 33 | 0.020 |
Why?
|
Lung Diseases | 1 | 2019 | 1884 | 0.020 |
Why?
|
Immunoblotting | 1 | 2012 | 1683 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2007 | 5169 | 0.020 |
Why?
|
Colonoscopy | 1 | 1997 | 1365 | 0.020 |
Why?
|
Health Promotion | 1 | 2021 | 2194 | 0.020 |
Why?
|
Odds Ratio | 2 | 2014 | 9846 | 0.020 |
Why?
|
Cause of Death | 2 | 2012 | 3571 | 0.020 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2010 | 362 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2014 | 1969 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4187 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6931 | 0.020 |
Why?
|
Eye | 1 | 2012 | 728 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8662 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 2997 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2016 | 1989 | 0.020 |
Why?
|
Calcineurin | 1 | 2008 | 226 | 0.020 |
Why?
|
Macrocyclic Compounds | 1 | 2007 | 72 | 0.020 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1995 | 1130 | 0.020 |
Why?
|
Receptors, Complement 3b | 1 | 2007 | 145 | 0.020 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2007 | 230 | 0.020 |
Why?
|
Erythroblasts | 1 | 2007 | 150 | 0.020 |
Why?
|
Colon | 1 | 1995 | 1773 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2271 | 0.020 |
Why?
|
Erythrocytes | 1 | 2016 | 2452 | 0.020 |
Why?
|
Mice, Nude | 1 | 2013 | 3689 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2007 | 295 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2016 | 2968 | 0.020 |
Why?
|
Skin Ulcer | 1 | 2007 | 118 | 0.020 |
Why?
|
Research Design | 2 | 2013 | 5979 | 0.020 |
Why?
|
Paraneoplastic Syndromes | 1 | 2007 | 150 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6191 | 0.020 |
Why?
|
Immune System | 1 | 2012 | 804 | 0.020 |
Why?
|
Canada | 1 | 2011 | 2061 | 0.020 |
Why?
|
Adenoma | 1 | 1997 | 2168 | 0.020 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2007 | 462 | 0.020 |
Why?
|
Professional Staff Committees | 1 | 2005 | 38 | 0.020 |
Why?
|
Liver | 2 | 2012 | 7470 | 0.020 |
Why?
|
Phosphorylation | 1 | 2017 | 8436 | 0.020 |
Why?
|
Eczema | 1 | 2007 | 229 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3701 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2007 | 876 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2010 | 804 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2003 | 7153 | 0.020 |
Why?
|
Serologic Tests | 1 | 2007 | 374 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 1997 | 2542 | 0.020 |
Why?
|
Epidermis | 1 | 2007 | 527 | 0.020 |
Why?
|
Plasma Exchange | 1 | 2005 | 155 | 0.020 |
Why?
|
Exercise | 1 | 2021 | 5611 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2016 | 14720 | 0.020 |
Why?
|
Blood Transfusion | 1 | 2011 | 1296 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2009 | 1342 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2723 | 0.020 |
Why?
|
Hyperplasia | 1 | 2007 | 1183 | 0.020 |
Why?
|
Sick Role | 1 | 2005 | 237 | 0.020 |
Why?
|
Health Services for the Aged | 1 | 1987 | 269 | 0.020 |
Why?
|
Self-Assessment | 1 | 2006 | 390 | 0.010 |
Why?
|
Organ Size | 1 | 2009 | 2253 | 0.010 |
Why?
|
Albumins | 1 | 2007 | 568 | 0.010 |
Why?
|
Protein Binding | 1 | 2016 | 9387 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2023 | 12220 | 0.010 |
Why?
|
Down-Regulation | 1 | 2011 | 3001 | 0.010 |
Why?
|
Immunotherapy | 1 | 2019 | 4414 | 0.010 |
Why?
|
Glycoproteins | 1 | 2012 | 2260 | 0.010 |
Why?
|
Rabbits | 1 | 2010 | 4886 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 3 | 2012 | 35342 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6365 | 0.010 |
Why?
|
Hospitalization | 1 | 2023 | 10232 | 0.010 |
Why?
|
Pyridines | 1 | 2015 | 2818 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2009 | 1366 | 0.010 |
Why?
|
Quality-Adjusted Life Years | 1 | 2009 | 1679 | 0.010 |
Why?
|
Major Histocompatibility Complex | 1 | 2006 | 935 | 0.010 |
Why?
|
Intestines | 1 | 2012 | 1923 | 0.010 |
Why?
|
Receptors, Interleukin-2 | 1 | 2004 | 573 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2010 | 20774 | 0.010 |
Why?
|
Autoantibodies | 1 | 2010 | 2036 | 0.010 |
Why?
|
Geriatric Assessment | 1 | 1990 | 1369 | 0.010 |
Why?
|
Hydroxylamine | 1 | 2001 | 16 | 0.010 |
Why?
|
Salmo salar | 1 | 2001 | 8 | 0.010 |
Why?
|
Macropodidae | 1 | 2001 | 12 | 0.010 |
Why?
|
Encephalomyocarditis virus | 1 | 2001 | 20 | 0.010 |
Why?
|
Cardiovirus Infections | 1 | 2001 | 19 | 0.010 |
Why?
|
Alkylation | 1 | 2001 | 86 | 0.010 |
Why?
|
Isomerism | 1 | 2001 | 201 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8328 | 0.010 |
Why?
|
Double-Blind Method | 1 | 1995 | 12017 | 0.010 |
Why?
|
Administration, Oral | 1 | 2009 | 3913 | 0.010 |
Why?
|
Drug Interactions | 1 | 2006 | 1458 | 0.010 |
Why?
|
Creatinine | 1 | 2006 | 1916 | 0.010 |
Why?
|
Hydrolysis | 1 | 2001 | 682 | 0.010 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2001 | 1086 | 0.010 |
Why?
|
Family | 1 | 2011 | 3144 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15494 | 0.010 |
Why?
|
Interferon-beta | 1 | 2001 | 323 | 0.010 |
Why?
|
Life Change Events | 1 | 2005 | 937 | 0.010 |
Why?
|
Referral and Consultation | 2 | 1990 | 3527 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 2001 | 13814 | 0.010 |
Why?
|
Amino Acid Motifs | 1 | 2001 | 936 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2001 | 18112 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 1999 | 8829 | 0.010 |
Why?
|
Biological Assay | 1 | 2001 | 652 | 0.010 |
Why?
|
Prevalence | 1 | 2015 | 15194 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2001 | 2049 | 0.010 |
Why?
|
Rhode Island | 2 | 1990 | 347 | 0.010 |
Why?
|
Rats, Inbred Lew | 1 | 1999 | 1161 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 16665 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2001 | 2837 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2001 | 2257 | 0.010 |
Why?
|
Reoperation | 1 | 2006 | 4200 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2001 | 2552 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 19862 | 0.010 |
Why?
|
Ultrasonography | 1 | 2009 | 5978 | 0.010 |
Why?
|
Interleukin-10 | 1 | 2001 | 1200 | 0.010 |
Why?
|
Amphotericin B | 1 | 1976 | 137 | 0.010 |
Why?
|
Boston | 1 | 2008 | 9305 | 0.010 |
Why?
|
Biomedical Research | 1 | 2011 | 3306 | 0.010 |
Why?
|
Rats, Wistar | 1 | 1999 | 1902 | 0.010 |
Why?
|
Lipids | 1 | 2006 | 3302 | 0.010 |
Why?
|
Phenotype | 1 | 2012 | 16331 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2005 | 2575 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2006 | 2536 | 0.010 |
Why?
|
Databases, Factual | 1 | 2008 | 7716 | 0.010 |
Why?
|
Emotions | 1 | 2005 | 2657 | 0.010 |
Why?
|
Drug Eruptions | 1 | 1976 | 295 | 0.010 |
Why?
|
Cystic Fibrosis | 1 | 2001 | 1178 | 0.010 |
Why?
|
Binding Sites | 1 | 2001 | 6115 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2001 | 2556 | 0.010 |
Why?
|
Anxiety | 1 | 2005 | 4279 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2007 | 11470 | 0.010 |
Why?
|
Base Sequence | 1 | 2001 | 12797 | 0.010 |
Why?
|
Mass Screening | 1 | 2005 | 5238 | 0.010 |
Why?
|
Equipment Design | 1 | 1997 | 3582 | 0.010 |
Why?
|
DNA | 1 | 2001 | 7289 | 0.000 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2005 | 4248 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 15108 | 0.000 |
Why?
|
Random Allocation | 1 | 1990 | 2425 | 0.000 |
Why?
|
Depression | 1 | 2005 | 7733 | 0.000 |
Why?
|
Internal Medicine | 1 | 1990 | 1009 | 0.000 |
Why?
|
Eosinophilia | 1 | 1976 | 531 | 0.000 |
Why?
|